September 14, 2010 (FinancialWire) (Investrend Information Syndicate) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — LightPath Technologies, Inc. (NASDAQ: LPTH), a manufacturer, distributor and integrator of patented optical components and assemblies, announced yesterday that sales of its precision molded aspheres and optical assemblies in China have more than doubled over the past six months compared to the prior six month period. The company says it is is experiencing “strong growth” for its molded aspheric lenses in the targeted market segments of consumer and industrial laser tools, medical equipment, and telecommunications.

LightPath said that the market for aspheric lenses in Asia is expected to top $280 Million by 2011, and that increased adoption among multiple market segments in China is helping to drive up demand for LightPath's products. According to the company, molded aspheric lenses provide new cost savings over traditional high volume spherical doublet and triplet lenses without sacrificing performance.

Jim Gaynor, CEO of LightPath Technologies, commented, “We are pleased to report that acceptance of molded aspheres as a replacement for spherical doublets and triplets has surpassed our initial expectations. Over the last six months, we have more than doubled our sales into the Chinese market. The continued success of our application-specific products demonstrates our capabilities in providing a low cost platform for the manufacture of high-precision glass molded aspheric lenses. We anticipate continued growth in industrial laser tools and medical equipment segments as well as resurgence in the telecommunications segment in the near future. We are also excited by the initial acceptance of our new line of blue lenses.”

The company states that, through its wholly-owned Shanghai-based subsidiary, it operates a low-cost, high-volume ISO 9001:2008 certified production facility and clean room with direct access to the Asian marketplace. The company further states that its Shanghai facility is presently at 48% of total capacity, and that LightPath is currently doubling its press capacity to ensure it will keep pace with the anticipated unit volume demand for high-volume, low-cost lenses used in industrial tools, telecommunications infrastructure and other commercial applications.

Broadcast note: LightPath will host a conference call Thursday, September 16th, to discuss the company's financial and operational results for the fourth quarter of fiscal 2010. To hear the call go to http://www.investrend.com/synd0003 and select the “Broadcast Alert” link.

The dial-in number is 1-877-407-8033. The international dial-in number is 1-201-689-8033. Participants are recommended to dial-in approximately 5 to 10 minutes prior to the start of the call. A replay of the call will be available approximately three hours after completion through September 23, 2010. To listen to the replay, dial 1-877-660-6853 (within the U.S.) and 1-201-612-7415 (international calls), and enter account # 286 and conference ID # 355799.

More about LPTH: Other FinancialWire(tm) news about LightPath is accessible via The FinancialWire(tm) search function (at http://www.financialwire.net/?s=lpthnas), additional information and independent research on LightPath is available via Investrend Syndications (at http://www.investrend.com/synd0003), and official information and company filings from LightPath are accessible via the SEC website (at http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001366669).

=========

Equity research on any public company is available through the Shareholders Research Alliance (go to http://www.investrend.com/synd0004 for more information).  Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html).  Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[ssryrsyr] [pltfrm] [lpthnas] [synd0003] [bsdarrgnmnt] [grdnstscrts] [ndstrls] [mnfctrng] [ndstrlspplssrvcs] [tchnlgy] [advnctchnlgy] [biomedphrm] [ftrdnwswnd]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.